Biomea Fusion (BMEA) News Today $4.23 +0.15 (+3.68%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Brokerages Set Biomea Fusion, Inc. (NASDAQ:BMEA) PT at $39.36December 20 at 1:31 AM | americanbankingnews.comBarclays Remains a Hold on Biomea Fusion (BMEA)December 18 at 9:27 PM | markets.businessinsider.comBiomea Fusion (BMEA) Receives a Buy from Truist FinancialDecember 18 at 9:27 PM | markets.businessinsider.comBiomea Fusion, Inc.: Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 DiabetesDecember 18 at 3:12 AM | finanznachrichten.deWhat's Driving Biomea Fusion? Stock Soars 25%December 17, 2024 | markets.businessinsider.comBiomea Fusion's (BMEA) Buy Rating Reiterated at D. Boral CapitalD. Boral Capital restated a "buy" rating and set a $128.00 price objective on shares of Biomea Fusion in a research report on Tuesday.December 17, 2024 | marketbeat.comBiomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 DiabetesDecember 17, 2024 | globenewswire.comBiomea Fusion, Inc. (NASDAQ:BMEA) Given Consensus Rating of "Buy" by AnalystsBiomea Fusion, Inc. (NASDAQ:BMEA - Get Free Report) has earned a consensus recommendation of "Buy" from the thirteen research firms that are presently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating, nine have issued a buy rating and twoDecember 17, 2024 | marketbeat.comBiomea Fusion (NASDAQ:BMEA) Given Buy Rating at HC WainwrightDecember 17, 2024 | americanbankingnews.comBiomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)December 16, 2024 | globenewswire.comBiomea Fusion's (BMEA) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $40.00 price target on shares of Biomea Fusion in a research note on Monday.December 16, 2024 | marketbeat.comBiomea Fusion, Inc. (NASDAQ:BMEA) Short Interest Up 5.4% in NovemberBiomea Fusion, Inc. (NASDAQ:BMEA - Get Free Report) was the recipient of a large growth in short interest in the month of November. As of November 30th, there was short interest totalling 9,920,000 shares, a growth of 5.4% from the November 15th total of 9,410,000 shares. Based on an average daily trading volume, of 773,600 shares, the short-interest ratio is currently 12.8 days. Currently, 31.4% of the company's stock are sold short.December 16, 2024 | marketbeat.comD. Boral maintains Buy rating, $128 target on Biomea Fusion after presentationsDecember 14, 2024 | markets.businessinsider.comBiomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)December 12, 2024 | globenewswire.comHC Wainwright Reaffirms Buy Rating for Biomea Fusion (NASDAQ:BMEA)December 12, 2024 | americanbankingnews.comOppenheimer Keeps Their Buy Rating on Biomea Fusion (BMEA)December 11, 2024 | markets.businessinsider.comBiomea Fusion (BMEA) Gets a Hold from BarclaysDecember 11, 2024 | markets.businessinsider.comBiomea Fusion's (BMEA) "Buy" Rating Reaffirmed at D. Boral CapitalDecember 11, 2024 | americanbankingnews.comBiomea Fusion (NASDAQ:BMEA) Earns "Buy" Rating from D. Boral CapitalD. Boral Capital restated a "buy" rating and set a $128.00 price objective on shares of Biomea Fusion in a report on Tuesday.December 10, 2024 | marketbeat.comBiomea Fusion announces preliminary COVALENT-103 study dataDecember 10, 2024 | markets.businessinsider.comBiomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute LeukemiaDecember 9, 2024 | globenewswire.comBiomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute LeukemiaDecember 6, 2024 | globenewswire.comBiomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)December 2, 2024 | globenewswire.comScotiabank Sticks to Their Buy Rating for Biomea Fusion (BMEA)November 26, 2024 | markets.businessinsider.comBiomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Recommendation of "Buy" from BrokeragesShares of Biomea Fusion, Inc. (NASDAQ:BMEA - Get Free Report) have earned an average rating of "Buy" from the twelve analysts that are currently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two havNovember 22, 2024 | marketbeat.comPositive Buy Recommendation for Biomea Fusion Amid Promising Diabetes Treatment Developments in COVALENT-111 Phase 2 TrialNovember 22, 2024 | markets.businessinsider.comHC Wainwright Reiterates Buy Rating for Biomea Fusion (NASDAQ:BMEA)HC Wainwright reiterated a "buy" rating and set a $40.00 target price on shares of Biomea Fusion in a research note on Thursday.November 21, 2024 | marketbeat.comBiomea Fusion’s icovamenib shows efficacy in Type 2 diabetes trialNovember 19, 2024 | markets.businessinsider.comWe're A Little Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn RateNovember 13, 2024 | finance.yahoo.comBiomea Fusion FY2024 EPS Estimate Raised by HC WainwrightBiomea Fusion, Inc. (NASDAQ:BMEA - Free Report) - Equities researchers at HC Wainwright raised their FY2024 earnings per share estimates for Biomea Fusion in a report issued on Thursday, October 31st. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings of ($3.97November 4, 2024 | marketbeat.comBiomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)November 1, 2024 | globenewswire.comTruist Financial Remains a Buy on Biomea Fusion (BMEA)October 31, 2024 | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on Biomea Fusion (BMEA)October 31, 2024 | markets.businessinsider.comBiomea Fusion, Inc.: Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate HighlightsOctober 31, 2024 | finanznachrichten.deBiomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist CandidateOctober 30, 2024 | globenewswire.comBarclays Keeps Their Hold Rating on Biomea Fusion (BMEA)October 30, 2024 | markets.businessinsider.comBiomea Fusion price target raised to $11 from $9 at BarclaysOctober 30, 2024 | markets.businessinsider.comBarclays Increases Biomea Fusion (NASDAQ:BMEA) Price Target to $11.00Barclays lifted their price target on shares of Biomea Fusion from $9.00 to $11.00 and gave the company an "equal weight" rating in a research note on Wednesday.October 30, 2024 | marketbeat.comBiomea Fusion (NASDAQ:BMEA) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPSBiomea Fusion (NASDAQ:BMEA - Get Free Report) announced its quarterly earnings results on Tuesday. The company reported ($0.91) earnings per share for the quarter, beating analysts' consensus estimates of ($0.94) by $0.03.October 30, 2024 | marketbeat.comBiomea Fusion Reports Q3 2024 Financial ResultsOctober 30, 2024 | msn.comBiomea Fusion Reports Third Quarter 2024 Financial Results and Corporate HighlightsOctober 29, 2024 | globenewswire.comBiomea Fusion options imply 6.1% move in share price post-earningsOctober 29, 2024 | markets.businessinsider.comBiomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Rating of "Buy" from BrokeragesBiomea Fusion, Inc. (NASDAQ:BMEA - Get Free Report) has earned an average recommendation of "Buy" from the twelve ratings firms that are presently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation, eight have issued a buy recommendationOctober 28, 2024 | marketbeat.comBuy Recommendation for Biomea Fusion: Promising Clinical Developments of Icovamenib in Diabetes TreatmentOctober 22, 2024 | markets.businessinsider.comBiomea Fusion's (BMEA) Buy Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $40.00 price objective on shares of Biomea Fusion in a research note on Tuesday.October 22, 2024 | marketbeat.comBiomea Fusion announces approval of ‘icovamenib’ as INN for BMF-219October 21, 2024 | markets.businessinsider.comBiomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219October 21, 2024 | globenewswire.comBiomea Fusion, Inc. (NASDAQ:BMEA) Shares Purchased by Griffin Asset Management Inc.Griffin Asset Management Inc. raised its stake in shares of Biomea Fusion, Inc. (NASDAQ:BMEA - Free Report) by 147.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 96,070 shares of the company's stock afterOctober 16, 2024 | marketbeat.comBiomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1 RA-Based TherapyOctober 15, 2024 | globenewswire.comSquarepoint Ops LLC Invests $237,000 in Biomea Fusion, Inc. (NASDAQ:BMEA)Squarepoint Ops LLC bought a new stake in shares of Biomea Fusion, Inc. (NASDAQ:BMEA - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 52,628 shares of the company's stock, vaOctober 13, 2024 | marketbeat.com Get Biomea Fusion News Delivered to You Automatically Sign up to receive the latest news and ratings for BMEA and its competitors with MarketBeat's FREE daily newsletter. Email Address URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen. Register for the FREE Workshop Now & get $10 in Bitcoin BMEA Media Mentions By Week BMEA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BMEA News Sentiment▼0.450.61▲Average Medical News Sentiment BMEA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BMEA Articles This Week▼154▲BMEA Articles Average Week Get Biomea Fusion News Delivered to You Automatically Sign up to receive the latest news and ratings for BMEA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PLRX News ETNB News RLAY News AVXL News IMNM News KURA News KROS News TYRA News ERAS News CRON News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BMEA) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomea Fusion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biomea Fusion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
